Showing results (1-10 of 73) with videos related to
Sort By:
Pageof 8
Molecular Cancer Therapeutics|August 6, 2011
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agentsThapi D Rao, Nestor Rosales, David R SpriggsPlos One|May 13, 2015
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionThapi D Rao, Huasong Tian, Xun Ma, et al.Molecular Cancer Therapeutics|April 12, 2022
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective AgentsThapi D Rao, Mengyao Xu, Stephanie Eng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2010
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigenAlena A Chekmasova, Thapi D Rao, Yan Nikhamin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Inclusion of patients with brain metastases in phase I trials: an unmet needMrinal M Gounder, David R SpriggsBioessays : News and Reviews in Molecular, Cellular and Developmental Biology|June 29, 2004
Non-kinase second-messenger signaling: new pathways with new promiseGregory M Springett, Hiroaki Kawasaki, David R SpriggsACS Chemical Biology|June 16, 2017
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer GrowthThapi Dharma Rao, Alberto Fernández-Tejada, Abram Axelrod, et al.Cancer|August 24, 2005
Presentation and subsequent publication rates of phase I oncology clinical trialsLuis H Camacho, Jennifer Bacik, Alexander Cheung, et al.Journal of Translational Medicine|April 19, 2015
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancerMythili Koneru, Roisin O'Cearbhaill, Swati Pendharkar, et al.Clinical Trials (London, England)|October 2, 2008
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studiesAlexia Iasonos, Andrew S Wilton, Elyn R Riedel, et al.Pageof 8